ColoCare Study - Colorectal Cancer Cohort

Conditions

Colorectal Cancer

Keywords

Colorectal cancer, rectosigmoid, rectum, colon

Brief summary

ColoCare is an international prospective cohort study of stage I-IV colorectal cancer patients (ICD-10 C18-C20).

Detailed description

The ColoCare Study is a multicenter initiative establishing an international cohort of colorectal cancer (CRC) patients for interdisciplinary studies of CRC prognosis and outcomes with sites at the Fred Hutchinson Cancer Center, Seattle (Washington, USA), H. Lee Moffitt Cancer Center and Research Institute, Tampa (Florida, USA), the University Hospital Heidelberg (Germany), the Huntsman Cancer Institute (Utah, USA), the Cedars-Senai Medical Center (California, USA), University of Washington St. Louis (Missouri, USA), and University of Tennessee (Tennessee, USA). Aims: The ColoCare Study investigates clinical outcomes, including disease-free and overall survival, predictors of cancer recurrence, survival, health-related quality-of-life and treatment toxicities. In addition, cross-sectional analyses of biomarkers and/or health behaviors are undertaken. Patients will be recruited if their age range is 18-89 years. For patients recruited after 09/01/2021 the age range is between 18-69 years, except if they participate in specific sub-studies or in studies for older cancer patients. Recruitment of patients \>70 years was re-initiated after 06/2024 in anticipation of R01 grant funding. Patients are recruited at baseline (time of first diagnosis) and followed for up to 5 years at regular timepoints (3m, 6m, 12m, 24m, 36m, 48m, 60m). The cohort includes a comprehensive collection of specimens and data. For the U01 renewal phase (start September 2021) we specifically focus on the recruitment of minorities (early-onset patients, African American patients, Hispanic patients) and patients with rectal cancer. Furthermore, we will have an overall focus on questionnaire assessment at baseline, 12, and 60 months and intensive medical chart abstraction 24 months and 60. months after enrollment into the study.

Peoples AR, Damerell V, Ose J, Siegel EM, Lin T, Hardikar S, Himbert C, Ilozumba MN, Schrotz-King P, Crowder SL, Toriola AT, Shibata D, Li CI, Byrd DA, Aßmann ES, Jim HSL, Figueiredo JC, Ulrich CM, Gigic B.

2026-02-01

10.1002/cam4.71576

Associations of Biomarkers of Systemic Inflammation, Angiogenesis, and Cell‐to‐Cell Adhesion With Tumor Budding Among Early‐Onset and Later‐Onset Colorectal Cancer Patients

Oliver Hausmann, Pauline P. Schobert, Jennifer Ose, Caroline Himbert, Maria Pletneva et al. (27 authors)

Cancer Medicine2025-09-01

10.1002/cam4.71267

Associations of Biomarkers of Systemic Inflammation, Angiogenesis, and Cell-to-Cell Adhesion With Tumor Budding Among Early-Onset and Later-Onset Colorectal Cancer Patients

Hausmann, Oda, Schobert, Pauline P., Ose, Jennifer, Himbert, Caroline, Pletneva, Maria et al. (27 authors)

SerWisS (University of Applied Sciences and Arts Hannover)2025-01-01

10.25968/opus-3707

Functional quality of life among newly diagnosed young adult colorectal cancer survivors compared to older adults: results from the ColoCare Study.

Oswald LB, Bloomer A, Li X, Jean-Baptiste E, Trujillo G, Felder S, Small BJ, Ose J, Hardikar S, Strehli I, Huang LC, Mooney K, Mutch MG, Chao D, Cohen SA, Karchi M, Wood EH, Damerell V, Loroña NC, Gong J, Toriola AT, Li CI, Shibata D, Schneider M, Gigic B, Figueiredo JC, Jim HSL, Ulrich CM, Siegel EM.

2024-04-193 citations

10.1007/s00520-024-08511-5

Relationships Among Physical Activity, Sleep, and Cancer-related Fatigue: Results From the International ColoCare Study

Sylvia L. Crowder, Xiaoyin Li, Caroline Himbert, Richard Viskochil, Aasha I. Hoogland et al. (22 authors)

Annals of Behavioral Medicine2023-12-2311 citations

10.1093/abm/kaad068

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 89 Years

Healthy volunteers

No

Inclusion criteria

1. Age 18-89 years; for patients recruited after 09/01/2021 the age range is 18-69 years. Recruitment of patients 70 years and older was maintained for specific sub-studies and re-initiated for specific R01 grant funding in \ 06/2024 2. Men and women 3. Newly-diagnosed colon or rectal cancer (stages I-IV); CRC in treatment (FHCRC and HCI) 4. English (FHCRC, Moffitt, HCI, Cedars-Sinai, WashU St. Louis) or German (University Hospital Heidelberg)-speaking; 5. mentally/physically able to consent and participate.

Exclusion criteria

* if one of the above in not fulfilled * insufficient language or consent capacity

Design outcomes

Primary

Measure	Time frame
Disease-free and overall survival	up to 10 years
Recurrence	up to 5 years

Secondary

Measure	Time frame
Health-related quality of life	at 0, 3, 6, 12, 24, 36, 48, 60 months post recruitment
Treatment toxicities	up to 5 years post treatment

Countries

Germany, United States

Contacts

Primary ContactCornelia Ulrich, MS, PhD

neli.ulrich@hci.utah.edu(801) 213-5716

Backup ContactSheetal Hardikar, PhD

sheetal.hardikar@hci.utah.edu

Outcome results